Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.

ABSTRACT:

Background

Whether the high cost of cancer drugs is commensurate with their value to patients, which has become the focus of public concern. We aimed to assess the value of new cancer drugs approved for solid cancer in China and to explore the association between price and value of drugs.

Methods

We identified all new drugs for solid tumor that approved by the China's National Medical Products Administration (NMPA) between 2016 and 2020. The value of these drugs was assessed according to the American Society of Clinical Oncology Value Framework (ASCO-VF) and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). We calculated Cohen's κ statistic to describe agreement between the two frameworks. Spearman's correlation coefficient was

SUBMITTER: Luo J 

PROVIDER: S-EPMC9998930 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature